// App-Quantinova.ai

1590 : Amlexanox As a Possible Breakthrough Drug for MLL/AF4-Positive Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Hayato Tamai

Principal Investigators

  • Hiroki Yamaguchi

  • Koichi Miyake

  • Miyuki Takatori

  • Tomoaki Kitano

  • Syunsuke Yui

  • Keiko Fukunaga

  • Kazutaka Nakayama

  • Koiti Inokuchi

Medical Centers

  • Department of Biochemistry and Molecular Biology, Division of Gene Therapy Research Center for Advanced Medical Technology, Nippon Medical School, Tokyo, Japan

  • Department of Urology, Nippon Medical School Hospital, Tokyo, Japan

  • Research Center for Life Science, Nippon Medical School, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of differentiation 45

  • Histone-lysine N-methyltransferase 2A

  • S100 Calcium Binding Protein A6

  • Tumor necrosis factor

Drug/Treatment

  • Amlexanox

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved